January 05, 2022
The UCLA CARE Center strives to make significant contributions to the development and conduct of HIV treatment, prevention, COVID-19 studies. The ultimate goal of these studies is to develop and clinically evaluate new treatments and novel therapeutic approaches for HIV prevention, HIV treatment, HIV-related diseases and co-infections, and complications of therapy to improve patients’ quality of l
December 08, 2021
In The Know A community webinar highlighting new insights in HIV and COVID research PROGRAMClick on the presentation title or presenter below to watch that specific presentation. Opening RemarksDr. Judith Currier An Update on COVID-19 ResearchDr. Eric Daar New Approaches in HIV PreventionDr. Raphael Landovitz An Update on COVID-19 ResearchDr. David Goodman-Meza An Update on HIV Cure
October 03, 2021
Long-acting pre-exposure prophylaxis (PrEP) is not only a long sought-after measure of HIV control in the infectious disease community—it’s a now tangible opportunity that would alter both diagnostics and care. In an interview with Contagion during IDWeek 2021, Raphael J. Landovitz, MD, MSc, of the UCLA Center for Clinical AIDS Research & Education, reviewed his own presentation on the current
Click on the presentation title or presenter below to watch that specific presentation.
Dr. Judith Currier
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI). Interested in Volunteering? We are looking for HIV+ people who are taking antiretroviral treatment (ART) and whose viral load is undetectable. The goal is to find out if IL-15 is safe alone or when used in combination with another treatment called broadly neutralizing antibodies (bNAbs). Participants will receive 8 doses of IL-15 given every 3 weeks. Half of the participants will be randomly assigned to also receive the bNAbs with it. After completing these treatments, participants will temporarily stop taking their HIV medicine (ART) and will be evaluated to see how well this treatment controls their viral load. Basic Eligibility Criteria: Age: 18-65 years old Status: HIV Positive Continuous HIV treatment: at least 96 weeks Viral load: Undetectable at least 96 weeks Coinfection: No active hepatitis B or C infection CD4 count: More than 500 Principal Investigator: Kara Chew, MD, MS For more information, please contact the UCLA CARE Center: [email protected] 310-843-2015 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
Antibodies that develop naturally against HIV recognize and attach to one part of the virus so that the body’s immune system can try to attack it. Antibodies are usually made by a person’s own immune system, but they can also be manufactured as a drug. SAR441236 has been manufactured to attach to three parts of the HIV virus at the same time, and to neutralize (or block) the ability of the virus to infect more cells. A5377 is the first study of SAR441236 in humans. This study will enroll two groups of people with HIV: Arm A—people who are on an anti-HIV regimen with an undetectable HIV viral load will receive either SAR441236 or placebo in four increasing dosing groups; and Arm B—people who have never received anti-HIV medications will receive SAR441236 in four increasing dosing groups. Interested in Volunteering? This UCLA research study is for people living with HIV who are not currently on ART. You may qualify if you: Are 18 years of age or older Are HIV+ Have a CD4+ cell count of at least 350 Are not currently taking antiretrovirals (ART) Are willing to start ART after 28 days on the study Have no Hepatitis B or C infection Principal Investigator: Raphael Landovitz, MD, MSc For more information, contact the UCLA CARE Center at: [email protected] 310-557-9062 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
Having trouble taking your HIV medication every day? Might MONTHLY injections be right for you? This study is for people living with HIV to determine if LONG-ACTING, MONTHLY INJECTABLE medications will be more successful at keeping the viral load undetectable than the "standard" daily oral medications for people who have difficulty taking pills every day for HIV. Eligibility You may be eligible to participate in this study if you are: 18 years of age or older HIV + and have a DETECTABLE viral load Have trouble taking HIV medication regularly The study will last between 6 months and 3 ½ years depending on successful completion of each milestone in the study Principal Investigator: Raphael Landovitz, MD, MSc For more information, contact the UCLA CARE Center at: [email protected] 310-557-9062 There are limitations to the confidentiality of email communications. Do not include any sensitive health information if you choose to contact the study team via email. If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.